Effect of pirfenidone on treatment-emergent (TE) all-cause mortality (ACM) in patients with idiopathic pulmonary fibrosis (IPF): Pooled data analysis from ASCEND and CAPACITY
Steven Nathan (Falls Church, United States of America), Steven D. Nathan, Carlo Albera, Williamson Z. Bradford, Ulrich Costabel, Roland M. du Bois, Elizabeth A. Fagan, Ian Glaspole, Marilyn K. Glassberg, David Kardatzke, Talmadge E. King Jr., Klaus-Uwe Kirchgaessler, Lisa H. Lancaster, David J. Lederer, Carlos A. Pereira, Jeffrey J. Swigris, Dominique Valeyre, Paul W. Noble
Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Steven Nathan (Falls Church, United States of America), Steven D. Nathan, Carlo Albera, Williamson Z. Bradford, Ulrich Costabel, Roland M. du Bois, Elizabeth A. Fagan, Ian Glaspole, Marilyn K. Glassberg, David Kardatzke, Talmadge E. King Jr., Klaus-Uwe Kirchgaessler, Lisa H. Lancaster, David J. Lederer, Carlos A. Pereira, Jeffrey J. Swigris, Dominique Valeyre, Paul W. Noble. Effect of pirfenidone on treatment-emergent (TE) all-cause mortality (ACM) in patients with idiopathic pulmonary fibrosis (IPF): Pooled data analysis from ASCEND and CAPACITY. Eur Respir J 2015; 46: Suppl. 59, 4490
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: